HUYABIO International is the leader in accelerating the global development of novel biopharmaceutical product opportunities originating in China enabling faster, more cost-effective, and lower-risk drug development in the global markets. Through extensive collaboration with biopharmaceutical, academic, and commercial organizations, it has built the largest China-sourced compound portfolio covering all therapeutic areas. With offices in the US, Japan, South Korea, Canada, Ireland, and several strategic locations across China, including Shanghai, Beijing, Suzhou, Guangzhou, and Wuhan, HUYABIO International has become a partner of choice to accelerate product development and maximize value globally. 沪亚生物国际是推进中国原创生物医药进行全球化共同开发的领军企业，能以较快的速度、更经济的成本和较低的风险在全球市场进行药物开发。通过与中国医药领域产、学、商各界的精诚合作，沪亚生物国际建立了最大的涵盖全治疗领域的中国原创化合物资源组合。公司在美国、日本、韩国、加拿大、爱尔兰，以及中国的几个战略要地包括上海、北京、苏州、广州和武汉都设有办事处。沪亚生物国际已成为加速产品开发并在全球范围实现产品价值最大化的首选合作伙伴。